Clinical approvals for 2016 harvests by 5 pharmaceutical companies

Medicine sonfebruaal 4th by the impact of clinical self-examination, a large number of varieties of the normal market time was delayed, and even led to some segments of the pharmaceutical industry in the new varieties brokenIn 2016, only 3,770 drug companies filed for processing, and clinical applications were significantly lower than in 2015In this case, if the pharmaceutical company has a few clinical pieces in hand, naturally can be for the winter through the big test to add a few pieces of protectionToday, we focus on the clinical approvals obtained by Hengrui, Haizheng, Fosun, Lizhu, Renfu and other five luxury pharmaceutical companies in 2016Hengrui Medicineabout Hengrui's situation, the author in the previous article "there is a pharmaceutical company, called batch professional household" provided more detailed information, including the clinical approval of the harvest, the withdrawal of varieties, the 2016 winning province, etc, here is no longer detailedInterested friends can click directly to viewthe clinical approvals received by Hengrui in 2016Haizheng PharmaceuticalsHaizheng Pharmaceuticals received a total of 35 clinical approvals in 2016, the total research and development costs behind these approvals amounted to 411.6 million yuanHaizheng project and research and development varieties are really good, but if you can not turn research and development into production, can not turn production into sales, can not turn sales into profits, and finally are on paperthe clinical approvals received by Hai isFosunMedicineFosun Pharma in 2016 a total of 19 clinical approvals, the total research and development costs behind these approvals of 290.8 million yuanThe HLX07 (Anti-EGFR Humanization Monoclonal Antibody) injection is a biomodified monoantigen developed by Fuhong Hanxuan and has been clinically carried out simultaneously in the FDA, Taiwan and mainland ChinaOverall, Fosun's research and development investment tends to focus on biologic drugs, and has placed a big betthe clinical approvals received by Fosun in 2016
Lizhu GroupLizhu Group in 2016 a total of 9 clinical approvals, the research and development costs behind these approvals totaled 2493.4 million yuanFrom the cost composition point of view, Lizhu in the biological medicine also under the blood2016 Lizhu received clinical approvals
people fu medicinepeople Fu Medicine in 2016 a total of 10 clinical approvals, these approvals behind the total research and development costs of 86.3 million yuanThe research and development of human medicine is mainly concentrated in the field of anesthesia and analgesia, and gradually begins to involve the field of small moleculesthe clinical approval received in 2016
the above five companies in the pharmaceutical industry has a certain representative, especially Haizheng Pharmaceuticals, the company's projects and declarations of varieties are very good, the company is also willing to invest money, but the company in the production, sales and operation of the problem so that such research and development investment in the future can produce returns left a great deal of doubtLizhu and Fosun's research and development focus on biosimilars, the domestic in recent years biosimilar research and development has become the largest hot spot, the difficulty of research and development of such drugs and the funds needed to invest is not the general small companies can afford to playOn the contrary, Hengrui did not make a big money to this field, Hengrui to get the batch of varieties are mainly ophthalmology, respiratory medicine, cardiovascular, gynaecology, anesthesia, tumor
and other departments of medication the batch of people are mainly concentrated in Yichang People's Fu's anaesthetic sedation, analgesic products above, the PARP preparation is also one of the world's hottest small molecules this year